Roth Capital Initiates Coverage On GlycoMimetics with Buy Rating, Announces $12 Price Target

Roth Capital initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Buy rating and a $12 price target.

Benzinga · 11/14/2019 11:28

Roth Capital initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Buy rating and a $12 price target.